Rosmantuzumab - OncoMed Pharmaceuticals

Drug Profile

Rosmantuzumab - OncoMed Pharmaceuticals

Alternative Names: Anti-RSPO3 antibody – Oncomed; OMP-131R10; Rosmantuzumab

Latest Information Update: 12 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OncoMed Pharmaceuticals
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action RSPO3 protein inhibitors; Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Colorectal cancer; Solid tumours

Most Recent Events

  • 05 Apr 2017 Pharmacodynamics data from a preclinical trial in Colorectal cancer presented at the American Association for Cancer Research Annual Meeting (AACR-2017)
  • 29 Nov 2016 Interim safety, efficacy and pharmacokinetics results presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
  • 08 Jan 2016 Interim pharmacodynamics data from a preclinical study in Cancer released by OncoMed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top